IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Conditions
- Advanced Endometrial Carcinoma
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Melanoma
- Advanced Ovarian Clear Cell Adenocarcinoma
- Chondrosarcoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Refractory Endometrial Carcinoma
- Refractory Head and Neck Squamous Cell Carcinoma
- Refractory Melanoma
- Refractory Ovarian Clear Cell Adenocarcinoma
- Refractory Ovarian High Grade Serous Adenocarcinoma
- Stage III Ovarian Cancer AJCC v8
- Stage III Uterine Corpus Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA Uterine Corpus Cancer AJCC v8
- Stage IIIA1 Ovarian Cancer AJCC v8
- Stage IIIA2 Ovarian Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIB Uterine Corpus Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IIIC Uterine Corpus Cancer AJCC v8
- Stage IIIC1 Uterine Corpus Cancer AJCC v8
- Stage IIIC2 Uterine Corpus Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Uterine Corpus Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Uterine Corpus Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
- BIOLOGICAL: Bevacizumab
- DRUG: Glutaminase-1 Inhibitor IACS-6274
- DRUG: Paclitaxel
- DRUG: Capivasertib
Sponsor
M.D. Anderson Cancer Center